The Mayo Clinic Cancer Center (MCCC) oversees clinical trial conduct and participant safety of cancer clinical trials conducted at Mayo Clinic through the center's Data and Safety Monitoring (DSM) system. Data and safety monitoring is required for all types of clinical trials (pilot and phase l - lll ) . Monitoring of studies is proportionate to the risk associated with each study. Per NIH policy, a Data and Safety Monitoring Board (DSMB) is established for multi-site clinical trials involving interventions that entail potential risks to participants. The DSM system is in place and provides oversight of clinical research conducted through the MCCC. The process of oversight has been developed to ensure patient safety while promoting research with a high level of quality and integrity. The system is constructed in a manner that promotes ongoing review of each of the components. This permits timely changes in procedures and policies as the regulatory environment changes. It also provides a mechanism to identify internal areas of inconsistency, promoting modifications to the MCCC procedures to address these issues. DSM activities are accomplished through the center's Data and Safety Monitoring Board (DSMB) and Data and Safety Monitoring Committee (DSMC). The Data and Safety Monitoring Committee (DSMC) operates as a component of the DSM system and provides oversight related to the review of changes for investigator brochures, deviation reporting, and the review of adverse events across studies that require changes to the informed consent form. As opposed to the DSMB focus on elements of safety of individual trials, the DSMC is an added value service to investigators in that adverse events across studies for any given agent and investigator brochure (IB) changes that would mandate consent form or protocol procedure changes are identified and addressed to ensure consistency, standardization, and efficiencies. The Data and Safety Monitoring Board (DSMB) operates as a component of the DSM system and is structured to serve all pilot, phase I, II, and III interventional trials for which a DSMB does not exist and for which Mayo is the data center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682948
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$86,097
Indirect Cost
$32,002
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications